The following information is being disclosed for the purposes of AIM Rule 26.
Tern PLC shares in issue - 330,338,101 ordinary shares of 0.02p and each share is entitled to one vote.
Tern PLC has not applied or agreed, to have any of its securities admitted to trading on any other exchange or trading platform than AIM.
The number of shares not in public hands is 21,100,898 shares, 6.4%.
Significant Shareholders |
Number of Shares |
% |
Al Sisto | 10,416,666 | 3.2 |
This information was updated on 16th November 2020.
There are no restrictions on the transferability of the Company's ordinary shares.
Year-end: |
31 December |
AGM: |
8 June 2020 |
Interims announced: |
21 September 2020 |
21 September 2020 Tern PLC Interim Accounts to 30 June 2020
7 May 2020 Tern PLC Report and Accounts 2019
25 September 2019 Tern PLC Interim Accounts to 30 June 2019
25 March 2019 Tern PLC Report and Accounts 2018
17 September 2018 Tern PLC Interim Accounts to 30 June 2018
27 March 2018 Tern PLC Report and Accounts 2017
4 September 2017 Tern PLC Interim Accounts to 30 June 2017
17 February 2017 Tern PLC Annual Report and Accounts 2016
26 July 2016 Tern PLC Interim Accounts to 30 June 2016
26 January 2016 Tern PLC Annual Report and Accounts 2015
5 August 2015 Tern PLC Interim Accounts to 30 June 2015
10 February 2015 Tern PLC Annual Report and Accounts 2014
Nominated Adviser and Broker
Allenby Capital Limited, 5 St. Helen's Place, London, EC3A 6AB
Financial PR
IFC Advisory, Birchin Court, 20 Birchin Lane, London, EC3V 9DU
Company Registrar
Share Registrars Ltd, The Courtyard, 17 West Street, Farnham, Surrey, GU9 7DR
Auditors
Nexia Smith & Williamson, 25 Moorgate, London, EC2R 6AY
Corporate Lawyers
Reed Smith, The Broadgate Tower, 20 Primrose Street, London, EC2A 2RS
Please contact Tern's financial PR agency, IFC Advisory in the first instance.
The Directors have been advised that Tern PLC is subject to the UK City Code on Takeovers and Mergers. The Board recognises the value and importance of high standards of corporate governance. Accordingly, the Board has adopted the Corporate Governance Code 2018 (“the Code”) published by the Quoted Company Alliance (“QCA”). For further details, please see the link below.
For more information, please contact us.
Click here for our Investing Policy.
Click here for further information on Corporate Governance. Updated 15 June 2020.
Please note, the information disclosed on this page is in accordance with Rule 26 of the AIM Rules for Companies and was last updated on 15 June 2020.
View our board of directors here.
The Board comprises four Executive Directors and two Non-Executive Directors. The Board manages the Company's affairs according to the schedule of matters reserved for its decision, including the approval of financial statements, acquisitions and disposals, authority levels for expenditure, and reviews of monthly and other management reports.
The Company holds board meetings periodically as issues arise which require the attention of the Board. The Board is responsible for the management of the business of the company, setting its strategic direction and establishing policy. It is the Board’s responsibility to oversee and monitor the financial position, the business and the affairs of the Company on behalf of the shareholders, to whom the Directors are accountable.
The Audit Committee and the Remuneration Committee both comprise Ian Ritchie and Alan Howarth and are both chaired by Alan Howarth.
See below for our current listing of constitutional documents:
Please see below for all admissions and circulars:
15.10.13 Tern Circular
31.07.13 R2710 SLME Circular
16.11.12 Silvermere Notice of General Meeting
02.08.11 Silvermere Admission Document
01.03.10 Core Circular March 2010
01.03.06 The Core Business plc Admission Document
To view Tern PLC Regulatory News please click here.
Tern PLC
Gridiron
One Pancras Square
London, N1C 4AG
e info@ternplc.com
t 0203 807 0222
The approval and rollout of the multiple Covid-19 vaccines has been a bright spot in a year which saw the world plunged into an unprecedented uncertainty. However, the current vaccines each have specific criteria which must be met in order to make sure they are effective, which has meant that the supply chain has had to consider smart ways to ensure successful delivery.
The past year has taught us many things about the healthcare sector – not least the extraordinary impact of big data analytics. As healthcare researchers and clinicians have gathered more data about Covid-19, from the genomic sequence of individual variants of the virus, to the typical progression of symptoms among different demographics, to the effects of various interventions, so the global response to the pandemic has become more intelligent and more efficient.
© Tern PLC | Sitemap | Terms & Conditions | Privacy Policy
B2B website design by Axon Garside